176 related articles for article (PubMed ID: 24643223)
1. HIV-1 genital shedding is suppressed in the setting of high genital antiretroviral drug concentrations throughout the menstrual cycle.
Sheth AN; Evans-Strickfaden T; Haaland R; Martin A; Gatcliffe C; Adesoye A; Omondi MW; Lupo LD; Danavall D; Easley K; Chen CY; Pau CP; Hart C; Ofotokun I
J Infect Dis; 2014 Sep; 210(5):736-44. PubMed ID: 24643223
[TBL] [Abstract][Full Text] [Related]
2. Antiretroviral drug exposure in the female genital tract: implications for oral pre- and post-exposure prophylaxis.
Dumond JB; Yeh RF; Patterson KB; Corbett AH; Jung BH; Rezk NL; Bridges AS; Stewart PW; Cohen MS; Kashuba AD
AIDS; 2007 Sep; 21(14):1899-907. PubMed ID: 17721097
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics of two common antiretroviral regimens in older HIV-infected patients: a pilot study.
Dumond JB; Adams JL; Prince HM; Kendrick RL; Wang R; Jennings SH; Malone S; White N; Sykes C; Corbett AH; Patterson KB; Forrest A; Kashuba AD
HIV Med; 2013 Aug; 14(7):401-9. PubMed ID: 23433482
[TBL] [Abstract][Full Text] [Related]
4. The Female Genital Tract Microbiome Is Associated With Vaginal Antiretroviral Drug Concentrations in Human Immunodeficiency Virus-Infected Women on Antiretroviral Therapy.
Donahue Carlson R; Sheth AN; Read TD; Frisch MB; Mehta CC; Martin A; Haaland RE; Patel AS; Pau CP; Kraft CS; Ofotokun I
J Infect Dis; 2017 Nov; 216(8):990-999. PubMed ID: 29029138
[TBL] [Abstract][Full Text] [Related]
5. Cervicovaginal HIV-1 shedding in women taking antiretroviral therapy in Burkina Faso: a longitudinal study.
Low AJ; Konate I; Nagot N; Weiss HA; Kania D; Vickerman P; Segondy M; Mabey D; Pillay D; Meda N; van de Perre P; Mayaud P;
J Acquir Immune Defic Syndr; 2014 Feb; 65(2):237-45. PubMed ID: 24226060
[TBL] [Abstract][Full Text] [Related]
6. Once-daily atazanavir/ritonavir compared with twice-daily lopinavir/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naive HIV-1-infected patients: 96-week efficacy and safety results of the CASTLE study.
Molina JM; Andrade-Villanueva J; Echevarria J; Chetchotisakd P; Corral J; David N; Moyle G; Mancini M; Percival L; Yang R; Wirtz V; Lataillade M; Absalon J; McGrath D;
J Acquir Immune Defic Syndr; 2010 Mar; 53(3):323-32. PubMed ID: 20032785
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of efficacy, safety, pharmacokinetics, and adherence in HIV-1-infected, antiretroviral-naïve patients treated with ritonavir-boosted atazanavir plus fixed-dose tenofovir DF/emtricitabine given once daily.
Elion R; Cohen C; Ward D; Ruane P; Ortiz R; Reddy YS; Ebrahimi R; McColl D; Kearney B; Fisher A; Flaherty J;
HIV Clin Trials; 2008; 9(4):213-24. PubMed ID: 18753116
[TBL] [Abstract][Full Text] [Related]
8. Relationship Between Genital Drug Concentrations and Cervical Cellular Immune Activation and Reconstitution in HIV-1-Infected Women on a Raltegravir Versus a Boosted Atazanavir Regimen.
Meditz AL; Palmer C; Predhomme J; Searls K; Kerr B; Seifert S; Caraway P; Gardner EM; MaWhinney S; Anderson PL
AIDS Res Hum Retroviruses; 2015 Oct; 31(10):1015-22. PubMed ID: 26059647
[TBL] [Abstract][Full Text] [Related]
9. Week 144 resistance analysis of elvitegravir/cobicistat/emtricitabine/tenofovir DF versus atazanavir+ritonavir+emtricitabine/tenofovir DF in antiretroviral-naïve patients.
Kulkarni R; Abram ME; McColl DJ; Barnes T; Fordyce MW; Szwarcberg J; Cheng AK; Miller MD; White KL
HIV Clin Trials; 2014; 15(5):218-30. PubMed ID: 25350960
[TBL] [Abstract][Full Text] [Related]
10. Herpes simplex virus type 2 (HSV-2) genital shedding in HSV-2-/HIV-1-co-infected women receiving effective combination antiretroviral therapy.
Péré H; Rascanu A; LeGoff J; Matta M; Bois F; Lortholary O; Leroy V; Launay O; Bélec L;
Int J STD AIDS; 2016 Mar; 27(3):178-85. PubMed ID: 25769886
[TBL] [Abstract][Full Text] [Related]
11. Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate versus ritonavir-boosted atazanavir plus co-formulated emtricitabine and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3, non-inferiority trial.
DeJesus E; Rockstroh JK; Henry K; Molina JM; Gathe J; Ramanathan S; Wei X; Yale K; Szwarcberg J; White K; Cheng AK; Kearney BP;
Lancet; 2012 Jun; 379(9835):2429-2438. PubMed ID: 22748590
[TBL] [Abstract][Full Text] [Related]
12. Steady-state amprenavir, tenofovir, and emtricitabine pharmacokinetics before and after reducing ritonavir boosting of a fosamprenavir/tenofovir/emtricitabine regimen from 200 mg to 100 mg once daily (TELEX II).
Parks DA; Jennings HC; Taylor C; Pakes GE; Acosta EP
HIV Clin Trials; 2009; 10(3):160-7. PubMed ID: 19632955
[TBL] [Abstract][Full Text] [Related]
13. Abacavir/lamivudine versus tenofovir DF/emtricitabine as part of combination regimens for initial treatment of HIV: final results.
Sax PE; Tierney C; Collier AC; Daar ES; Mollan K; Budhathoki C; Godfrey C; Jahed NC; Myers L; Katzenstein D; Farajallah A; Rooney JF; Ha B; Woodward WC; Feinberg J; Tashima K; Murphy RL; Fischl MA;
J Infect Dis; 2011 Oct; 204(8):1191-201. PubMed ID: 21917892
[TBL] [Abstract][Full Text] [Related]
14. Antiretroviral treatment interruptions predict female genital shedding of genotypically resistant HIV-1 RNA.
Graham SM; Jalalian-Lechak Z; Shafi J; Chohan V; Deya RW; Jaoko W; Mandaliya KN; Peshu NM; Overbaugh J; McClelland RS
J Acquir Immune Defic Syndr; 2012 Aug; 60(5):511-8. PubMed ID: 22592588
[TBL] [Abstract][Full Text] [Related]
15. Penetration of tenofovir and emtricitabine in mucosal tissues: implications for prevention of HIV-1 transmission.
Patterson KB; Prince HA; Kraft E; Jenkins AJ; Shaheen NJ; Rooney JF; Cohen MS; Kashuba AD
Sci Transl Med; 2011 Dec; 3(112):112re4. PubMed ID: 22158861
[TBL] [Abstract][Full Text] [Related]
16. Prevalence, Magnitude, and Correlates of HIV-1 Genital Shedding in Women on Antiretroviral Therapy.
King CC; Ellington SR; Davis NL; Coombs RW; Pyra M; Hong T; Mugo N; Patel RC; Lingappa JR; Baeten JM; Kourtis AP;
J Infect Dis; 2017 Dec; 216(12):1534-1540. PubMed ID: 29240922
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics and safety of single-dose tenofovir disoproxil fumarate and emtricitabine in HIV-1-infected pregnant women and their infants.
Flynn PM; Mirochnick M; Shapiro DE; Bardeguez A; Rodman J; Robbins B; Huang S; Fiscus SA; Van Rompay KK; Rooney JF; Kearney B; Mofenson LM; Watts DH; Jean-Philippe P; Heckman B; Thorpe E; Cotter A; Purswani M;
Antimicrob Agents Chemother; 2011 Dec; 55(12):5914-22. PubMed ID: 21896911
[TBL] [Abstract][Full Text] [Related]
18. Tenofovir, emtricitabine, and darunavir/ritonavir pharmacokinetics in an HIV-infected patient after Roux-en-Y gastric bypass surgery.
MacBrayne CE; Blum JD; Kiser JJ
Ann Pharmacother; 2014 Jun; 48(6):816-9. PubMed ID: 24615629
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetics of emtricitabine, tenofovir, and GS-9137 following coadministration of emtricitabine/tenofovir disoproxil fumarate and ritonavir-boosted GS-9137.
Ramanathan S; Shen G; Cheng A; Kearney BP
J Acquir Immune Defic Syndr; 2007 Jul; 45(3):274-9. PubMed ID: 17414929
[TBL] [Abstract][Full Text] [Related]
20. Tenofovir-based preexposure prophylaxis for HIV infection among African women.
Marrazzo JM; Ramjee G; Richardson BA; Gomez K; Mgodi N; Nair G; Palanee T; Nakabiito C; van der Straten A; Noguchi L; Hendrix CW; Dai JY; Ganesh S; Mkhize B; Taljaard M; Parikh UM; Piper J; Mâsse B; Grossman C; Rooney J; Schwartz JL; Watts H; Marzinke MA; Hillier SL; McGowan IM; Chirenje ZM;
N Engl J Med; 2015 Feb; 372(6):509-18. PubMed ID: 25651245
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
